Lv, Dongwen http://orcid.org/0000-0003-4677-8996
Pal, Pratik
Liu, Xingui
Jia, Yannan
Thummuri, Dinesh
Zhang, Peiyi
Hu, Wanyi
Pei, Jing
Zhang, Qi http://orcid.org/0000-0002-7918-8952
Zhou, Shuo
Khan, Sajid http://orcid.org/0000-0003-1331-8846
Zhang, Xuan http://orcid.org/0000-0001-6062-6708
Hua, Nan
Yang, Qingping
Arango, Sebastian
Zhang, Weizhou http://orcid.org/0000-0002-8236-0346
Nayak, Digant http://orcid.org/0000-0003-3680-0846
Olsen, Shaun K. http://orcid.org/0000-0002-1265-7101
Weintraub, Susan T.
Hromas, Robert
Konopleva, Marina http://orcid.org/0000-0002-9347-2212
Yuan, Yaxia
Zheng, Guangrong http://orcid.org/0000-0002-8106-6663
Zhou, Daohong http://orcid.org/0000-0002-2400-6461
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA241191, R01 AG063801, R01 CA205224, R01 GM115568, R01 GM128731, R01 CA200673, R01 CA203834)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Cancer Prevention and Research Institute of Texas (RR200030)
Article History
Received: 2 May 2021
Accepted: 5 November 2021
First Online: 25 November 2021
Competing interests
: D.L., P.P., X.L., D.T., P.Z., W.H., S.K., X.Z, Y.Y., G.Z., and D.Z. are inventors of the following patent and pending patent application for use of BCL-xL PROTACs as senolytic and antitumor agents: 1. COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF (Patent number: 10807977, Status: Granted, Applicant/Assignee: BioVentures, LLC, Inventors: Guangrong Zheng, Daohong Zhou, Xuan Zhang, Yingying Wang, Jianhui Chang). 2. THERAPEUTIC AGENTS AND METHODS OF TREATMENT (Patent number: 2020218367, Status: Pending, Applicant/Assignee: University of Florida Research Foundation, Inventors: Guangrong Zheng, Daohong Zhou, Pratik Pal, Xingui Liu, Dinesh Thummuri Wenyi Hu, Peiyi Zhang, Dongwen Lyu, Yaxia Yuan, and Xuan Zhang). Compound 753b is one of the BCL-xL/2 PROTACs disclosed in Patent number 2020218367. R.H., G.Z., and D.Z. are co-founders of and have equity in Dialectic Therapeutics, which develops BCL-xL/2 PROTACs to treat cancer. All other authors have no competing interests.